In pregnant patients, the impact of blood type and the presence of red blood cell antibodies influence the course of the pregnancy and the health of the fetus and newborn infant. Throughout history, haemolytic disease of the fetus and newborn has played a fundamental role in the discovery of the blood group antibodies and their cognate antigens. The mid-1900s were noted for the advent of Rh immunoglobulin. Now, the technological advancements in diagnosis and treatment of haemolytic disease of the fetus and newborn have provided the critical tools needed to support mothers with affected pregnancies. The knowledge of blood typing has been further refined with the explosion of understanding about blood group genes, particularly in the RH blood group. Genomic blood group typing, improvements in ultrasound technology and transfusion medicine progress have advanced the field. The care of women with potentially affected pregnancies has never been more robust. Despite this, the risk to the fetus is significant, and prevention strategies for maternal alloimmunization deserve continued attention.
Introduction
The potential for haemolytic disease of the fetus and newborn (HDFN) originates when red blood cell (RBC) alloimmunization of nonself blood group antigens occurs in a female. When she later becomes pregnant, if her fetus has inherited blood group antigens from the father that are incompatible with the maternal RBC antibodies, the IgG phase antibodies can cross the placenta and cause immune mediated destruction of the fetal RBCs. In severe forms of the disease, fetal anaemia can cause heart failure and ascites, also called hydrops fetalis. Infants who are affected postnatally may have significant anaemia that can require phototherapy, immune therapies and simple RBC and exchange transfusion.
The prevention of HDFN has never been more proactive and precise. Efforts focus on two main approaches: molecular testing and transfusion policy. Advanced testing using molecular technology have improved the ability to guide administration of the single most effective prevention strategy for HDFN, Rh immune globulin [1, 2] . Policies aimed at RBC antigen matching are used to prevent initial and additional RBC alloimmunization. This review will focus on the recent studies that are informing prevention activities and improving RhIg administration.
Advancements in precision
Molecular techniques and knowledge about blood group genes and resulting phenotypes have been sufficiently developed to provide precise clinical guidance about the need for RhIg. Using sensitive molecular methods, the circulating cell-free fetal DNA can be isolated from the peripheral blood sample of the mother. Once isolated, the fetal blood group genes, such as RHD can be analysed to predict the fetal RBC RHD blood type [3] . This method has been found to be highly precise [4] . A benefit of this approach is avoiding invasive procedures such as amniocentesis. Nationwide screening programs have been introduced in some countries and regions such as Denmark, the Netherlands, Norway and Finland; pregnant mothers who have an RhD negative blood type are offered cell-free DNA testing to predict the fetal RhD blood group status [5] [6] [7] [8] . The information is used to precisely determine whether RhIg administration is needed or can be omitted.
Other molecular techniques have focused on our expanding knowledge about RHD genetic variation in the mother that may render RhIg administration unnecessary in certain individuals. The RhD polypeptide is coded by the RHD gene that has 10 exons. Mutations in the RHD gene can lead to decreased expression of the RhD polypeptide on the surface of the RBC, termed 'weak D' [1] . In this situation, the RhD polypeptide carries all of the epitopes found in the conventional RhD polypeptide, but is present in overall fewer numbers. This can lead to agglutination based testing reactions results that are weak or negative when assessing the RhD blood type. Research has shown that mothers with weakly positive or indeterminate RhD blood types who carry one of the three weak D alleles-weak D type 1, 2 or 3-in the hemizygous or homozygous state are not at risk of forming anti-D when exposed to the conventional RhD polypeptide [9] . Thus, authors have suggested that women with serological weak D to be offered weak D genotype testing to define if she should be treated as RhD negative (when weak D 1-3 alleles are not detected) or RhD positive (when weak D 1-3 alleles are detected) (Fig. 1) . The American College of Obstetrics and Gynecology (ACOG) guidelines notes the potential of this approach to avoid unnecessary RhIg [10] . A financial modelling study suggests using RHD genotype testing to determine if they carry weak D types 1-3 is a cost-effective way to prevent unnecessary RhIg administration and the use of RhD negative blood products when transfusion is required if the genotyping result is done one time [11] . When weak D genotyping is done, it is important that the information is conveyed to the mother so her future blood typing results can be interpreted in conjunction with the precise blood typing information provided by the weak D genotype test.
When a mother is found to be alloimmunized to RhD at a prenatal visit, molecular testing can also be used to determine whether the fetus has the potential to be affected [12, 13] . When paternity is confirmed, and paternal sample is available, performing zygosity testing of the RHD gene (copy number) can provide valuable information about if the fetus has a 50% or 100% chance of inheriting the RHD gene from him. There are instances where the conventional zygosity testing targets are not present, thus laboratory assays must include molecular targets to detect the RHD gene in all of its configurations, including common silencing mutations, structural variants and rearrangements [14] . If the paternal zygosity finds him to be hemizygous, additional testing such as cell-free fetal DNA from the maternal blood sample or amniocentesis can be used to obtain fetal DNA for direct RHD genetic testing [15] . Importantly, non-invasive prenatal testing of the circulating cell-free fetal DNA avoids the risk associated with amniocentesis.
Genotyping of fetal DNA is also being used when the implicated antigen and maternal antibody are directed to blood groups other than RhD. For instance, in the UK, the national reference laboratory is able to test and predict fetal K, C, c, and E RBC phenotypes accurately using realtime polymerase chain reaction (PCR) on isolated fetal DNA and is using this information for clinical care [16] . Other reference laboratories can perform blood group genetic testing using fetal DNA obtained using amniocentesis.
Advancements in prevention
The policy of providing antigen matched or antigen negative RBCs for transfusion has been used to prevent RBC alloimmunization in a number of clinical settings. For females of childbearing potential (FCPs), the goal of extended antigen matching is to prevent her from forming RBC antibodies that may lead to HDFN in future pregnancies. The RBC selection policies typically include the K antigen, as is done in many European countries, but also may include C, E or c, although there is not a standard approach or policy [17, 18] . To determine the potential impact of extended RBC antigen matching policies for FCPs, the 'Blood Group Antigen Matching Influence on Gestational Outcomes' (AMIGO) study retrospectively analysed the causes of alloimmunization in women who had severe HDFN [18] .
The 14 centres were split into those that provide antigen matched (five centres) and those that do not (nine centres). In this study cohort, 293 mothers from 14 centres in seven countries had 425 pregnancies with severe HDFN defined as the fetus required intrauterine transfusion or after birth, an exchange transfusion. The majority of severe HDFN was found to be due to previous pregnancy (243/293, 83%), while only 3% (8/293) were due to previous transfusion. In 14% of affected women, the aetiology of RBC alloimmunization could not be isolated because the mother had had both previous pregnancy and previous transfusion. These data suggest a relatively low likelihood to significantly impact the rate of female alloimmunization by a policy of RBC selection with antigen matching. However, other authors in a single centre analysis have shown a larger attributable causality to transfusion; 48% of 214 pregnancies with sensitization to E, K or c had a history of transfusion [18] [19] [20] .
The AMIGO study also attempted to determine the impact of prospective antigen matching RBC selection policies on the later development of HDFN in previously transfused mothers. They study found that of the 50 transfused mothers, those who were cared for by centres that used antigen matching for the K antigen were not protected from HDFN caused by anti-K more than those transfused mothers who were cared for by centres that did not have a policy to provide K-negative RBCs for transfusion (13 K sensitized mothers at matching centres compared to 4 K sensitized mothers at nonmatching centres; OR: 2Á11 (0Á56-7Á91)) [18] . Further, when taking into account only mothers that had K antigen negative partners, there were too few cases to form a conclusion; one mother at matching centre and two at nonmatching centre. Because the study was a real world review of the effectiveness of match policies, an 'intention to match' attribution approach was used. This means that all transfusions given to women who received pregnancy care at matching centres were attributed to that centre. Thus, an interesting observation of the AMIGO cohort was that 49% of the mothers who received transfusions occurred in a region not covered by the MATCH centre's transfusion policies. For example, the mother received transfusion before she moved to a hospital where the matching centre provided care. The broader implications of these findings are that the authors did not find a protective effect of RBC matching policies, although there were few transfused subjects and many that had received transfusion in a region that does not match. Blood bank directors who are contemplating implementing matching policies for women and girls can use the findings of the AMIGO study and others to determine how best to proceed. The population level benefit for antigen matching appears low unless all centres worldwide ascribe to the matching approach. However, on the individual level and in populations that are stationary, the impact may be higher [17] (Table 1) . A RBC selection policy will have to broadly cover all girls and women, regardless of previous transfusion history and will be agnostic to the RBC phenotype of potential future partners, since this information is not available at the time of blood product selection, especially in emergencies. As RBC genotyping programs become more commonplace at the blood collection facilities, more antigen negative units may found in blood bank inventories, making implementation easier [21] . Future energy around broad based antigen matching transfusion policies throughout the world may improve results, but the use of antigen matching in a single hospital or regional areas alone, for example in the United States, will not provide a protection of the population, although it should protect the individual patient [22] . Prevention efforts can also focus on persons who already have predisposition to the disorder in order to prevent additional morbidity and mortality from worsening of the disease, also called second or third line prevention. In the case of HDFN, allosensitized mothers are considered to be at risk for additional alloimmunization because of the commonly accepted finding that certain persons appear to be predisposed to forming RBC antibodies. In a mathematical modelling study, the authors found that patients with previous alloimmunization are at significantly higher risk to form additional alloantibodies. The authors note that approximately 30% of transfusion recipients are potential responders; 13% of recipients have already made alloantibodies and the rest having a much higher rate of forming antibodies with additional transfusion events [23] .
When a pregnant sensitized mother requires IUT due to severe fetal anaemia, she may be exposed to additional foreign antigens during the procedure if some of the donor blood enters her circulation. These antibodies may cause additional incompatibility to the fetus and/or endanger future pregnancies. To prevent additional antibodies from forming, researchers have used maternally antigen matched RBCs. In a study of 212 women, Rh/K (D,C,c,E,e,K) RBCs were matched to the mother to be used for the IUT procedure [24] . Fifty-three (25%) of the mothers formed new antibodies; 52% were to non-Rh/K antigens-83% of these were presumed to be due to stimulation from the donor RBCs. Forty-eight per cent were directed at Rh/K antigens and presumed to be due to ongoing fetal stimulation. The authors next attempted to provide extended matched RBCs for IUT to prevent sensitization to the donor antigens. In this study, 69 women received Rh/K, Duffy, Kidd, S maternal antigen matched RBCs for IUT. There was a noted improvement when extended matching was undertaken, with only 4Á3% of the mothers who received extended antigen matched RBCs forming new antibodies. Unfortunately, when attempting to do extended antigen matching, finding the appropriate unit can be problematic and in 50% of the women an appropriate RBC product not available [25] .
Conclusions
Advancement in scientific knowledge about alloimmunization and improvements in molecular testing techniques have moved the care and prevention of alloimmunization in females who may have future pregnancies, or are already pregnant, forward. Additionally, monitoring affected pregnancies has improved with noninvasive ultrasound techniques of the fetal middle cerebral artery to allow timely detection of severe fetal anaemia so that treatment interventions can occur [26] . When intervention is required, IUT can effectively prevent most affected children from having long-term neurological sequela, although fetal hydrops continues to be a strong risk factor for negative neurological outcomes [27] .
In the blood bank, challenges remain. Because HDFN is typically set up by female allosensitization many months or years before the affected pregnancy occurs, linking cause and effect to prevent HDFN through transfusion policies has proven to be difficult. Creation of impactful transfusion policies may need broad stakeholder engagement. When resources are under a high degree of scrutiny, cost-effective strategies are needed. The population-based research studies linking transfusion and HDFN offer information that was previously not well understood and should support discussion and refinement of prevention strategies.
The future of HDFN care is increasingly precise as molecular testing for blood group genes is adopted into the prenatal care pathway. The positive effects of the clinical genotyping testing are improving care and will continue to be a focus of improvement activities for maternal and child health.
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